175 related articles for article (PubMed ID: 28697954)
21. Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys.
Ko MC; Woods JH; Fantegrossi WE; Galuska CM; Wichmann J; Prinssen EP
Neuropsychopharmacology; 2009 Aug; 34(9):2088-96. PubMed ID: 19279568
[TBL] [Abstract][Full Text] [Related]
22. Role of mu-opioid agonist efficacy on antinociceptive interactions between mu agonists and the nociceptin opioid peptide agonist Ro 64-6198 in rhesus monkeys.
Cornelissen JC; Steele FF; Tenney RD; Obeng S; Rice KC; Zhang Y; Banks ML
Eur J Pharmacol; 2019 Feb; 844():175-182. PubMed ID: 30552903
[TBL] [Abstract][Full Text] [Related]
23. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
[TBL] [Abstract][Full Text] [Related]
24. Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.
Schröder W; Lambert DG; Ko MC; Koch T
Br J Pharmacol; 2014 Aug; 171(16):3777-800. PubMed ID: 24762001
[TBL] [Abstract][Full Text] [Related]
25. Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands.
Asth L; Ruzza C; Malfacini D; Medeiros I; Guerrini R; Zaveri NT; Gavioli EC; Calo' G
Neuropharmacology; 2016 Jun; 105():434-442. PubMed ID: 26867504
[TBL] [Abstract][Full Text] [Related]
26. The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.
Lin AP; Ko MC
ACS Chem Neurosci; 2013 Feb; 4(2):214-24. PubMed ID: 23421672
[TBL] [Abstract][Full Text] [Related]
27. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
28. Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys.
Rizzi A; Sukhtankar DD; Ding H; Hayashida K; Ruzza C; Guerrini R; Calò G; Ko MC
Br J Pharmacol; 2015 Jul; 172(14):3661-70. PubMed ID: 25828800
[TBL] [Abstract][Full Text] [Related]
29. Involvement of the N/OFQ-NOP system in rat morphine antinociceptive tolerance: Are astrocytes the crossroad?
Micheli L; Lucarini E; Corti F; Ciccocioppo R; Calò G; Rizzi A; Ghelardini C; Di Cesare Mannelli L
Eur J Pharmacol; 2018 Mar; 823():79-86. PubMed ID: 29378191
[TBL] [Abstract][Full Text] [Related]
30. Nociceptin and the NOP receptor in aversive learning in mice.
Adem A; Madjid N; Kahl U; Holst S; Sadek B; Sandin J; Terenius L; Ögren SO
Eur Neuropsychopharmacol; 2017 Dec; 27(12):1298-1307. PubMed ID: 29102248
[TBL] [Abstract][Full Text] [Related]
31. Opioid-type Respiratory Depressant Side Effects of Cebranopadol in Rats Are Limited by Its Nociceptin/Orphanin FQ Peptide Receptor Agonist Activity.
Linz K; Schröder W; Frosch S; Christoph T
Anesthesiology; 2017 Apr; 126(4):708-715. PubMed ID: 28291086
[TBL] [Abstract][Full Text] [Related]
32. Characterization of the Discriminative Stimulus Effects of a NOP Receptor Agonist Ro 64-6198 in Rhesus Monkeys.
Saccone PA; Zelenock KA; Lindsey AM; Sulima A; Rice KC; Prinssen EP; Wichmann J; Woods JH
J Pharmacol Exp Ther; 2016 Apr; 357(1):17-23. PubMed ID: 26801398
[TBL] [Abstract][Full Text] [Related]
33. Novel Synthesis and Pharmacological Characterization of NOP Receptor Agonist 8-[(1S,3aS)-2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (Ro 64-6198).
Chang SD; Brieaddy LE; Harvey JD; Lewin AH; Mascarella SW; Seltzman HH; Reddy PA; Decker AM; McElhinny CJ; Zhong D; Peterson EE; Navarro HA; Bruchas MR; Carroll FI
ACS Chem Neurosci; 2015 Dec; 6(12):1956-64. PubMed ID: 26367173
[TBL] [Abstract][Full Text] [Related]
34. Ro 64-6198 [(1S,3aS)-8-(2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one] acts differently from nociceptin/orphanin FQ in rat periaqueductal gray slices.
Chiou LC; Chuang KC; Wichmann J; Adam G
J Pharmacol Exp Ther; 2004 Nov; 311(2):645-51. PubMed ID: 15254141
[TBL] [Abstract][Full Text] [Related]
35. BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine.
Chao PK; Chang HF; Chang WT; Yeh TK; Ou LC; Chuang JY; Tsu-An Hsu J; Tao PL; Loh HH; Shih C; Ueng SH; Yeh SH
Neuropharmacology; 2020 Apr; 166():107678. PubMed ID: 31278929
[TBL] [Abstract][Full Text] [Related]
36. A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism.
Fantinati A; Bianco S; Guerrini R; Salvadori S; Pacifico S; Cerlesi MC; Calo G; Trapella C
Sci Rep; 2017 May; 7(1):2416. PubMed ID: 28546566
[TBL] [Abstract][Full Text] [Related]
37. Changes in nociceptin/orphanin FQ levels in rat brain regions after acute and chronic cannabinoid treatment in conjunction with the development of antinociceptive tolerance.
Ulugol A; Topuz RD; Gunduz O; Kizilay G; Karadag HC
Fundam Clin Pharmacol; 2016 Dec; 30(6):537-548. PubMed ID: 27371029
[TBL] [Abstract][Full Text] [Related]
38. Synergistic interaction between DAMGO-NH
Li N; Xiao J; Niu J; Zhang M; Shi Y; Yu B; Zhang Q; Chen D; Zhang N; Fang Q
Peptides; 2023 Mar; 161():170943. PubMed ID: 36621672
[TBL] [Abstract][Full Text] [Related]
39. Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics.
Ding H; Kiguchi N; Dobbins M; Romero-Sandoval EA; Kishioka S; Ko MC
Drugs; 2023 Jun; 83(9):771-793. PubMed ID: 37209211
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist.
Rizzi A; Cerlesi MC; Ruzza C; Malfacini D; Ferrari F; Bianco S; Costa T; Guerrini R; Trapella C; Calo' G
Pharmacol Res Perspect; 2016 Aug; 4(4):e00247. PubMed ID: 28116100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
